ArticleDiabetologia2026
Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aims/hypothesisType 2 diabetes exhibits remarkable clinical heterogeneity, represented by distinct pathological subtypes. However, the precise molecular alterations underlying these subgroups at single-cell resolution remain poorly understood. In this study, we integrated clinical metadata from both healthy control groups and individuals with type 2 diabetes with pancreatic islet single-cell transcriptomes to explore subtype-associated molecular alterations across mild age-related diabetes (MARD), mild obesity-related diabetes (MOD), severe insulin-deficient diabetes (SIDD) and severe insulin-resistant diabetes (SIRD).
methodsWe applied the established type 2 diabetes clustering framework with independent validation against external centroids to evaluate subtype assignment accuracy across 43 pancreatic islet donors with type 2 diabetes. High-throughput single-cell RNA sequencing data comprising 131,083 cells from 32 pancreatic islet donors were subsequently analysed to systematically compare cellular composition and subtype-associated molecular perturbation patterns across these subgroups.
resultsFour type 2 diabetes subgroups were identified, and validation against external centroids confirmed high assignment concordance, with subtype mapping sensitivities ranging from 85.0% to 100.0% in the full dataset and from 91.7% to 100.0% in the single-cell RNA sequencing sub-cohort. Notably, SIDD displayed the most pronounced beta cell perturbations, characterised by dual facets of beta cell dysfunction: the depletion of mature beta cell subclusters and the erosion of global cellular identity of beta cells. These alterations were accompanied by systematic activation of autophagy, apoptosis and endoplasmic reticulum stress pathways, while energy metabolism and insulin secretion were significantly compromised in SIDD individuals. In contrast, the SIRD phenotype manifested primarily as metabolic hyperactivation with largely preserved beta cell maturity. Additionally, MOD demonstrated moderate beta cell perturbations, characterised by enriched ribosomal function and protein synthesis activity. MARD displayed the mildest molecular disruption, consistent with its mild clinical phenotype. CONCLUSIONS/
interpretationOur study provides an exploratory single-cell map of subtype-associated transcriptomic patterns in pancreatic islets across clinically defined type 2 diabetes subgroups. These findings serve as a valuable resource for future investigations exploring the cellular and molecular heterogeneity underlying type 2 diabetes pathogenesis.
Indexed as
Identifiers
42678439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.